Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)

Yusuke       Isshiki; Ari       Melnick
doi:10.2174/1568009620666210106122750
Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin B cell lymphoma (NHL), and manifests highly heterogeneous genetic/phenotypic characteristics as well as variable responses to conventional immunochemotherapy. Genetic profiling of DLBCL patients has revealed highly recurrent mutations of epigenetic regulator genes such as CREBBP, KMT2D, EZH2 and TET2. These mutations drive malignant transformation through aberrant epigenetic programming of B-cells and may influence clinical outcomes. These and other chromatin modifier genes also play critical roles in normal B-cells, as they undergo the various phenotypic transitions characteristic of the humoral immune response. Many of these functions have to do with impairing immune surveillance and may critically mediate resistance to immunotherapies. In this review, we describe how epigenetic dysfunction induces lymphomagenesis and discuss ways of implementing precision epigenetic therapies to reverse these immune resistant phenotypes.
Keywords: Diffuse large B cell lymphoma (DLBCL), epigenetics, cREBBP, eP300, kMT2D, eZH2, TET2, epigenetic heterogeneity.
« Previous Next »
Graphical Abstract

[1] 
Al-Hamadani, M.; Habermann, T.M.; Cerhan, J.R.; Macon, W.R.; Maurer, M.J.; Go, R.S. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am. J. Hematol.,  2015, 90(9), 790-795.
[http://dx.doi.org/10.1002/ajh.24086] [PMID: 26096944] 
[2] 
Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Kamburov, A.; Redd, R.A.; Lawrence, M.S.; Roemer, M.G.M.; Li, A.J.; Ziepert, M.; Staiger, A.M.; Wala, J.A.; Ducar, M.D.; Leshchiner, I.; Rheinbay, E.; Taylor-Weiner, A.; Coughlin, C.A.; Hess, J.M.; Pedamallu, C.S.; Livitz, D.; Rosebrock, D.; Rosenberg, M.; Tracy, A.A.; Horn, H.; van Hummelen, P.; Feldman, A.L.; Link, B.K.; Novak, A.J.; Cerhan, J.R.; Habermann, T.M.; Siebert, R.; Rosenwald, A.; Thorner, A.R.; Meyerson, M.L.; Golub, T.R.; Beroukhim, R.; Wulf, G.G.; Ott, G.; Rodig, S.J.; Monti, S.; Neuberg, D.S.; Loeffler, M.; Pfreundschuh, M.; Trümper, L.; Getz, G.; Shipp, M.A. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med.,  2018, 24(5), 679-690.
[http://dx.doi.org/10.1038/s41591-018-0016-8] [PMID: 29713087] 
[3] 
Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kasbekar, M.; Young, R.M.; Shaffer, A.L.; Hodson, D.J.; Xiao, W.; Yu, X.; Yang, Y.; Zhao, H.; Xu, W.; Liu, X.; Zhou, B.; Du, W.; Chan, W.C.; Jaffe, E.S.; Gascoyne, R.D.; Connors, J.M.; Campo, E.; Lopez-Guillermo, A.; Rosenwald, A.; Ott, G.; Delabie, J.; Rimsza, L.M.; Tay Kuang Wei, K.; Zelenetz, A.D.; Leonard, J.P.; Bartlett, N.L.; Tran, B.; Shetty, J.; Zhao, Y.; Soppet, D.R.; Pittaluga, S.; Wilson, W.H.; Staudt, L.M. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N. Engl. J. Med.,  2018, 378(15), 1396-1407.
[http://dx.doi.org/10.1056/NEJMoa1801445] [PMID: 29641966] 
[4] 
Mlynarczyk, C.; Fontán, L.; Melnick, A. Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunol. Rev.,  2019, 288(1), 214-239.
[http://dx.doi.org/10.1111/imr.12755] [PMID: 30874354] 
[5] 
Reddy, A; Zhang, J; Davis, NS; Moffitt, AB; Love, CL; Waldrop, A Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell,  2017, 171(2), 481-94.
[6] 
Morin, R.D.; Mendez-Lago, M.; Mungall, A.J.; Goya, R.; Mungall, K.L.; Corbett, R.D.; Johnson, N.A.; Severson, T.M.; Chiu, R.; Field, M.; Jackman, S.; Krzywinski, M.; Scott, D.W.; Trinh, D.L.; Tamura-Wells, J.; Li, S.; Firme, M.R.; Rogic, S.; Griffith, M.; Chan, S.; Yakovenko, O.; Meyer, I.M.; Zhao, E.Y.; Smailus, D.; Moksa, M.; Chittaranjan, S.; Rimsza, L.; Brooks-Wilson, A.; Spinelli, J.J.; Ben-Neriah, S.; Meissner, B.; Woolcock, B.; Boyle, M.; McDonald, H.; Tam, A.; Zhao, Y.; Delaney, A.; Zeng, T.; Tse, K.; Butterfield, Y.; Birol, I.; Holt, R.; Schein, J.; Horsman, D.E.; Moore, R.; Jones, S.J.; Connors, J.M.; Hirst, M.; Gascoyne, R.D.; Marra, M.A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature,  2011, 476(7360), 298-303.
[http://dx.doi.org/10.1038/nature10351] [PMID: 21796119] 
[7] 
Lohr, J.G.; Stojanov, P.; Lawrence, M.S.; Auclair, D.; Chapuy, B.; Sougnez, C.; Cruz-Gordillo, P.; Knoechel, B.; Asmann, Y.W.; Slager, S.L.; Novak, A.J.; Dogan, A.; Ansell, S.M.; Link, B.K.; Zou, L.; Gould, J.; Saksena, G.; Stransky, N.; Rangel-Escareño, C.; Fernandez-Lopez, J.C.; Hidalgo-Miranda, A.; Melendez-Zajgla, J.; Hernández-Lemus, E.; Schwarz-Cruz y Celis, A.; Imaz-Rosshandler, I.; Ojesina, A.I.; Jung, J.; Pedamallu, C.S.; Lander, E.S.; Habermann, T.M.; Cerhan, J.R.; Shipp, M.A.; Getz, G.; Golub, T.R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA,  2012, 109(10), 3879-3884.
[http://dx.doi.org/10.1073/pnas.1121343109] [PMID: 22343534] 
[8] 
Hatzi, K.; Melnick, A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol. Med.,  2014, 20(6), 343-352.
[http://dx.doi.org/10.1016/j.molmed.2014.03.001] [PMID: 24698494] 
[9] 
Hatzi, K.; Jiang, Y.; Huang, C.; Garrett-Bakelman, F.; Gearhart, M.D.; Giannopoulou, E.G.; Zumbo, P.; Kirouac, K.; Bhaskara, S.; Polo, J.M.; Kormaksson, M.; MacKerell, A.D., Jr; Xue, F.; Mason, C.E.; Hiebert, S.W.; Prive, G.G.; Cerchietti, L.; Bardwell, V.J.; Elemento, O.; Melnick, A. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep.,  2013, 4(3), 578-588.
[http://dx.doi.org/10.1016/j.celrep.2013.06.016] [PMID: 23911289] 
[10] 
Jiang, Y.; Ortega-Molina, A.; Geng, H.; Ying, H.Y.; Hatzi, K.; Parsa, S.; McNally, D.; Wang, L.; Doane, A.S.; Agirre, X.; Teater, M.; Meydan, C.; Li, Z.; Poloway, D.; Wang, S.; Ennishi, D.; Scott, D.W.; Stengel, K.R.; Kranz, J.E.; Holson, E.; Sharma, S.; Young, J.W.; Chu, C.S.; Roeder, R.G.; Shaknovich, R.; Hiebert, S.W.; Gascoyne, R.D.; Tam, W.; Elemento, O.; Wendel, H.G.; Melnick, A.M. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discov.,  2017, 7(1), 38-53.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0975] [PMID: 27733359] 
[11] 
Zhang, J.; Vlasevska, S.; Wells, V.A.; Nataraj, S.; Holmes, A.B.; Duval, R.; Meyer, S.N.; Mo, T.; Basso, K.; Brindle, P.K.; Hussein, S.; Dalla-Favera, R.; Pasqualucci, L. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov.,  2017, 7(3), 322-337.
[http://dx.doi.org/10.1158/2159-8290.CD-16-1417] [PMID: 28069569] 
[12] 
Mondello, P.; Tadros, S.; Teater, M.; Fontan, L.; Chang, A.Y.; Jain, N.; Yang, H.; Singh, S.; Ying, H.Y.; Chu, C.S.; Ma, M.C.J.; Toska, E.; Alig, S.; Durant, M.; de Stanchina, E.; Ghosh, S.; Mottok, A.; Nastoupil, L.; Neelapu, S.S.; Weigert, O.; Inghirami, G.; Baselga, J.; Younes, A.; Yee, C.; Dogan, A.; Scheinberg, D.A.; Roeder, R.G.; Melnick, A.M.; Green, M.R. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov.,  2020, 10(3), 440-459.
[http://dx.doi.org/10.1158/2159-8290.CD-19-0116] [PMID: 31915197] 
[13] 
Pasqualucci, L.; Dominguez-Sola, D.; Chiarenza, A.; Fabbri, G.; Grunn, A.; Trifonov, V.; Kasper, L.H.; Lerach, S.; Tang, H.; Ma, J.; Rossi, D.; Chadburn, A.; Murty, V.V.; Mullighan, C.G.; Gaidano, G.; Rabadan, R.; Brindle, P.K.; Dalla-Favera, R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature,  2011, 471(7337), 189-195.
[http://dx.doi.org/10.1038/nature09730] [PMID: 21390126] 
[14] 
Cerchietti, L.C.; Hatzi, K.; Caldas-Lopes, E.; Yang, S.N.; Figueroa, M.E.; Morin, R.D.; Hirst, M.; Mendez, L.; Shaknovich, R.; Cole, P.A.; Bhalla, K.; Gascoyne, R.D.; Marra, M.; Chiosis, G.; Melnick, A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J. Clin. Invest.,  2010, 120(12), 4569-4582.
[http://dx.doi.org/10.1172/JCI42869] [PMID: 21041953] 
[15] 
García-Ramírez, I.; Tadros, S.; González-Herrero, I.; Martín-Lorenzo, A.; Rodríguez-Hernández, G.; Moore, D.; Ruiz-Roca, L.; Blanco, O.; Alonso-López, D.; Rivas, J.L.; Hartert, K.; Duval, R.; Klinkebiel, D.; Bast, M.; Vose, J.; Lunning, M.; Fu, K.; Greiner, T.; Rodrigues-Lima, F.; Jiménez, R.; Criado, F.J.G.; Cenador, M.B.G.; Brindle, P.; Vicente-Dueñas, C.; Alizadeh, A.; Sánchez- García, I.; Green, M.R. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood,  2017, 129(19), 2645-2656.
[http://dx.doi.org/10.1182/blood-2016-08-733469] [PMID: 28288979] 
[16] 
Green, M.R.; Kihira, S.; Liu, C.L.; Nair, R.V.; Salari, R.; Gentles, A.J.; Irish, J.; Stehr, H.; Vicente-Dueñas, C.; Romero-Camarero, I.; Sanchez-Garcia, I.; Plevritis, S.K.; Arber, D.A.; Batzoglou, S.; Levy, R.; Alizadeh, A.A. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA,  2015, 112(10), E1116-E1125.
[http://dx.doi.org/10.1073/pnas.1501199112] [PMID: 25713363] 
[17] 
Meyer, SN; Scuoppo, C; Vlasevska, S; Bal, E; Holmes, AB; Holloman, M Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. Immunity,  2019, 51(3), 535-47.
[18] 
Froimchuk, E.; Jang, Y.; Ge, K. Histone H3 lysine 4 methyltransferase KMT2D. Gene,  2017, 627, 337-342.
[http://dx.doi.org/10.1016/j.gene.2017.06.056] [PMID: 28669924] 
[19] 
Ortega-Molina, A.; Boss, I.W.; Canela, A.; Pan, H.; Jiang, Y.; Zhao, C.; Jiang, M.; Hu, D.; Agirre, X.; Niesvizky, I.; Lee, J.E.; Chen, H.T.; Ennishi, D.; Scott, D.W.; Mottok, A.; Hother, C.; Liu, S.; Cao, X.J.; Tam, W.; Shaknovich, R.; Garcia, B.A.; Gascoyne, R.D.; Ge, K.; Shilatifard, A.; Elemento, O.; Nussenzweig, A.; Melnick, A.M.; Wendel, H.G. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med.,  2015, 21(10), 1199-1208.
[http://dx.doi.org/10.1038/nm.3943] [PMID: 26366710] 
[20] 
Zhang, J.; Dominguez-Sola, D.; Hussein, S.; Lee, J.E.; Holmes, A.B.; Bansal, M.; Vlasevska, S.; Mo, T.; Tang, H.; Basso, K.; Ge, K.; Dalla-Favera, R.; Pasqualucci, L. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med.,  2015, 21(10), 1190-1198.
[http://dx.doi.org/10.1038/nm.3940] [PMID: 26366712] 
[21] 
Hatzi, K.; Geng, H.; Doane, A.S.; Meydan, C.; LaRiviere, R.; Cardenas, M.; Duy, C.; Shen, H.; Vidal, M.N.C.; Baslan, T.; Mohammad, H.P.; Kruger, R.G.; Shaknovich, R.; Haberman, A.M.; Inghirami, G.; Lowe, S.W.; Melnick, A.M. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat. Immunol.,  2019, 20(1), 86-96.
[http://dx.doi.org/10.1038/s41590-018-0273-1] [PMID: 30538335] 
[22] 
Di Croce, L.; Helin, K. Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol.,  2013, 20(10), 1147-1155.
[http://dx.doi.org/10.1038/nsmb.2669] [PMID: 24096405] 
[23] 
Morin, R.D.; Johnson, N.A.; Severson, T.M.; Mungall, A.J.; An, J.; Goya, R.; Paul, J.E.; Boyle, M.; Woolcock, B.W.; Kuchenbauer, F.; Yap, D.; Humphries, R.K.; Griffith, O.L.; Shah, S.; Zhu, H.; Kimbara, M.; Shashkin, P.; Charlot, J.F.; Tcherpakov, M.; Corbett, R.; Tam, A.; Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.; Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D.E.; Connors, J.M.; Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R.D.; Marra, M.A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet.,  2010, 42(2), 181-185.
[http://dx.doi.org/10.1038/ng.518] [PMID: 20081860] 
[24] 
Béguelin, W.; Popovic, R.; Teater, M.; Jiang, Y.; Bunting, K.L.; Rosen, M.; Shen, H.; Yang, S.N.; Wang, L.; Ezponda, T.; Martinez-Garcia, E.; Zhang, H.; Zheng, Y.; Verma, S.K.; McCabe, M.T.; Ott, H.M.; Van Aller, G.S.; Kruger, R.G.; Liu, Y.; McHugh, C.F.; Scott, D.W.; Chung, Y.R.; Kelleher, N.; Shaknovich, R.; Creasy, C.L.; Gascoyne, R.D.; Wong, K.K.; Cerchietti, L.; Levine, R.L.; Abdel-Wahab, O.; Licht, J.D.; Elemento, O.; Melnick, A.M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell,  2013, 23(5), 677-692.
[http://dx.doi.org/10.1016/j.ccr.2013.04.011] [PMID: 23680150] 
[25] 
Béguelin, W.; Teater, M.; Gearhart, M.D.; Calvo Fernández, M.T.; Goldstein, R.L.; Cárdenas, M.G.; Hatzi, K.; Rosen, M.; Shen, H.; Corcoran, C.M.; Hamline, M.Y.; Gascoyne, R.D.; Levine, R.L.; Abdel-Wahab, O.; Licht, J.D.; Shaknovich, R.; Elemento, O.; Bardwell, V.J.; Melnick, A.M. EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis. Cancer Cell,  2016, 30(2), 197-213.
[http://dx.doi.org/10.1016/j.ccell.2016.07.006] [PMID: 27505670] 
[26] 
Béguelin, W.; Rivas, M.A.; Calvo Fernández, M.T.; Teater, M.; Purwada, A.; Redmond, D.; Shen, H.; Challman, M.F.; Elemento, O.; Singh, A.; Melnick, A.M. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat. Commun.,  2017, 8(1), 877.
[http://dx.doi.org/10.1038/s41467-017-01029-x] [PMID: 29026085] 
[27] 
Caganova, M.; Carrisi, C.; Varano, G.; Mainoldi, F.; Zanardi, F.; Germain, P.L.; George, L.; Alberghini, F.; Ferrarini, L.; Talukder, A.K.; Ponzoni, M.; Testa, G.; Nojima, T.; Doglioni, C.; Kitamura, D.; Toellner, K.M.; Su, I.H.; Casola, S. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest.,  2013, 123(12), 5009-5022.
[http://dx.doi.org/10.1172/JCI70626] [PMID: 24200695] 
[28] 
Beguelin, W; Teater, M; Meydan, C; Hoehn, KB; Phillip, JM; Soshnev, AA Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell,  2020, 37(5), 655-73.
[29] 
Morschhauser, F.; Salles, G.A.; Le Gouill, S.; Radford, J.A.; Mckay, P.; Cartron, G. Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). J. Clin. Oncol.,  2016, 34(15)
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.TPS7582] 
[30] 
Wright, GW; Huang, DW; Phelan, JD; Coulibaly, ZA; Roulland, S; Young, RM A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell,  2020, 37(4), 551-568.
[31] 
Dominguez, P.M.; Ghamlouch, H.; Rosikiewicz, W.; Kumar, P.; Béguelin, W.; Fontán, L.; Rivas, M.A.; Pawlikowska, P.; Armand, M.; Mouly, E.; Torres-Martin, M.; Doane, A.S.; Calvo Fernandez, M.T.; Durant, M.; Della-Valle, V.; Teater, M.; Cimmino, L.; Droin, N.; Tadros, S.; Motanagh, S.; Shih, A.H.; Rubin, M.A.; Tam, W.; Aifantis, I.; Levine, R.L.; Elemento, O.; Inghirami, G.; Green, M.R.; Figueroa, M.E.; Bernard, O.A.; Aoufouchi, S.; Li, S.; Shaknovich, R.; Melnick, A.M. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discov.,  2018, 8(12), 1632-1653.
[http://dx.doi.org/10.1158/2159-8290.CD-18-0657] [PMID: 30274972] 
[32] 
Rosikiewicz, W.; Chen, X.; Dominguez, P.M.; Ghamlouch, H.; Aoufouchi, S.; Bernard, O.A.; Melnick, A.; Li, S. TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. Sci. Adv.,  2020, 6(25), eaay5872.
[http://dx.doi.org/10.1126/sciadv.aay5872] [PMID: 32596441] 
[33] 
Hashwah, H.; Schmid, C.A.; Kasser, S.; Bertram, K.; Stelling, A.; Manz, M.G.; Müller, A. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc. Natl. Acad. Sci. USA,  2017, 114(36), 9701-9706.
[http://dx.doi.org/10.1073/pnas.1619555114] [PMID: 28831000] 
[34] 
Ennishi, D.; Takata, K.; Béguelin, W.; Duns, G.; Mottok, A.; Farinha, P.; Bashashati, A.; Saberi, S.; Boyle, M.; Meissner, B.; Ben-Neriah, S.; Woolcock, B.W.; Telenius, A.; Lai, D.; Teater, M.; Kridel, R.; Savage, K.J.; Sehn, L.H.; Morin, R.D.; Marra, M.A.; Shah, S.P.; Connors, J.M.; Gascoyne, R.D.; Scott, D.W.; Melnick, A.M.; Steidl, C. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov.,  2019, 9(4), 546-563.
[http://dx.doi.org/10.1158/2159-8290.CD-18-1090] [PMID: 30705065] 
[35] 
de Vos, S.; Forero-Torres, A.; Ansell, S.M.; Kahl, B.; Cheson, B.D.; Bartlett, N.L.; Furman, R.R.; Winter, J.N.; Kaplan, H.; Timmerman, J.; Whiting, N.C.; Drachman, J.G.; Advani, R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J. Hematol. Oncol.,  2014, 7, 44.
[http://dx.doi.org/10.1186/1756-8722-7-44] [PMID: 24919462] 
[36] 
Chambwe, N.; Kormaksson, M.; Geng, H.; De, S.; Michor, F.; Johnson, N.A.; Morin, R.D.; Scott, D.W.; Godley, L.A.; Gascoyne, R.D.; Melnick, A.; Campagne, F.; Shaknovich, R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood,  2014, 123(11), 1699-1708.
[http://dx.doi.org/10.1182/blood-2013-07-509885] [PMID: 24385541] 
[37] 
Clozel, T.; Yang, S.; Elstrom, R.L.; Tam, W.; Martin, P.; Kormaksson, M.; Banerjee, S.; Vasanthakumar, A.; Culjkovic, B.; Scott, D.W.; Wyman, S.; Leser, M.; Shaknovich, R.; Chadburn, A.; Tabbo, F.; Godley, L.A.; Gascoyne, R.D.; Borden, K.L.; Inghirami, G.; Leonard, J.P.; Melnick, A.; Cerchietti, L. Mechanism-based epigenetic chemosensitization therapy of diffuse large B- cell lymphoma. Cancer Discov.,  2013, 3(9), 1002-1019.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0117] [PMID: 23955273] 
[38] 
Stelling, A.; Wu, C.T.; Bertram, K.; Hashwah, H.; Theocharides, A.P.A.; Manz, M.G.; Tzankov, A.; Müller, A. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv.,  2019, 3(20), 3020-3032.
[http://dx.doi.org/10.1182/bloodadvances.2019000210] [PMID: 31648327] 
[39] 
Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; Jaffe, E.S. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood,  2016, 127(20), 2375-2390.
[http://dx.doi.org/10.1182/blood-2016-01-643569] [PMID: 26980727] 
[40] 
Ennishi, D.; Jiang, A.; Boyle, M.; Collinge, B.; Grande, B.M.; Ben-Neriah, S.; Rushton, C.; Tang, J.; Thomas, N.; Slack, G.W.; Farinha, P.; Takata, K.; Miyata-Takata, T.; Craig, J.; Mottok, A.; Meissner, B.; Saberi, S.; Bashashati, A.; Villa, D.; Savage, K.J.; Sehn, L.H.; Kridel, R.; Mungall, A.J.; Marra, M.A.; Shah, S.P.; Steidl, C.; Connors, J.M.; Gascoyne, R.D.; Morin, R.D.; Scott, D.W. Double-hit gene expression signature defines a distinct subgroup of germinal center B-Cell-like diffuse large B-cell lymphoma. J. Clin. Oncol.,  2019, 37(3), 190-201.
[http://dx.doi.org/10.1200/JCO.18.01583] [PMID: 30523716] 
[41] 
Sha, C.; Barrans, S.; Cucco, F.; Bentley, M.A.; Care, M.A.; Cummin, T.; Kennedy, H.; Thompson, J.S.; Uddin, R.; Worrillow, L.; Chalkley, R.; van Hoppe, M.; Ahmed, S.; Maishman, T.; Caddy, J.; Schuh, A.; Mamot, C.; Burton, C.; Tooze, R.; Davies, A.; Du, M.Q.; Johnson, P.W.M.; Westhead, D.R. Molecular high-grade B- Cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J. Clin. Oncol.,  2019, 37(3), 202-212.
[http://dx.doi.org/10.1200/JCO.18.01314] [PMID: 30523719] 
[42] 
Dagogo-Jack, I.; Shaw, A.T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol.,  2018, 15(2), 81-94.
[http://dx.doi.org/10.1038/nrclinonc.2017.166] [PMID: 29115304] 
[43] 
Landau, D.A.; Clement, K.; Ziller, M.J.; Boyle, P.; Fan, J.; Gu, H.; Stevenson, K.; Sougnez, C.; Wang, L.; Li, S.; Kotliar, D.; Zhang, W.; Ghandi, M.; Garraway, L.; Fernandes, S.M.; Livak, K.J.; Gabriel, S.; Gnirke, A.; Lander, E.S.; Brown, J.R.; Neuberg, D.; Kharchenko, P.V.; Hacohen, N.; Getz, G.; Meissner, A.; Wu, C.J. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell,  2014, 26(6), 813-825.
[http://dx.doi.org/10.1016/j.ccell.2014.10.012] [PMID: 25490447] 
[44] 
De, S.; Shaknovich, R.; Riester, M.; Elemento, O.; Geng, H.; Kormaksson, M.; Jiang, Y.; Woolcock, B.; Johnson, N.; Polo, J.M.; Cerchietti, L.; Gascoyne, R.D.; Melnick, A.; Michor, F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet.,  2013, 9(1), e1003137.
[http://dx.doi.org/10.1371/journal.pgen.1003137] [PMID: 23326238] 
[45] 
Pan, H.; Jiang, Y.; Boi, M.; Tabbò, F.; Redmond, D.; Nie, K.; Ladetto, M.; Chiappella, A.; Cerchietti, L.; Shaknovich, R.; Melnick, A.M.; Inghirami, G.G.; Tam, W.; Elemento, O. Epigenomic evolution in diffuse large B-cell lymphomas. Nat. Commun.,  2015, 6, 6921.
[http://dx.doi.org/10.1038/ncomms7921] [PMID: 25891015] 
[46] 
Queirós, A.C.; Beekman, R.; Vilarrasa-Blasi, R.; Duran-Ferrer, M.; Clot, G.; Merkel, A.; Raineri, E.; Russiñol, N.; Castellano, G.; Beà, S.; Navarro, A.; Kulis, M.; Verdaguer-Dot, N.; Jares, P.; Enjuanes, A.; Calasanz, M.J.; Bergmann, A.; Vater, I.; Salaverría, I.; van de Werken, H.J.G.; Wilson, W.H.; Datta, A.; Flicek, P.; Royo, R.; Martens, J.; Giné, E.; Lopez-Guillermo, A.; Stunnenberg, H.G.; Klapper, W.; Pott, C.; Heath, S.; Gut, I.G.; Siebert, R.; Campo, E.; Martín-Subero, J.I. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B Cell lineage. Cancer Cell,  2016, 30(5), 806-821.
[http://dx.doi.org/10.1016/j.ccell.2016.09.014] [PMID: 27846393] 
[47] 
Pastore, A.; Gaiti, F.; Lu, S.X.; Brand, R.M.; Kulm, S.; Chaligne, R.; Gu, H.; Huang, K.Y.; Stamenova, E.K.; Béguelin, W.; Jiang, Y.; Schulman, R.C.; Kim, K.T.; Alonso, A.; Allan, J.N.; Furman, R.R.; Gnirke, A.; Wu, C.J.; Melnick, A.M.; Meissner, A.; Bernstein, B.E.; Abdel-Wahab, O.; Landau, D.A. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat. Commun.,  2019, 10(1), 1874.
[http://dx.doi.org/10.1038/s41467-019-09645-5] [PMID: 31015400] 
[48] 
Shaknovich, R.; Cerchietti, L.; Tsikitas, L.; Kormaksson, M.; De, S.; Figueroa, M.E.; Ballon, G.; Yang, S.N.; Weinhold, N.; Reimers, M.; Clozel, T.; Luttrop, K.; Ekstrom, T.J.; Frank, J.; Vasanthakumar, A.; Godley, L.A.; Michor, F.; Elemento, O.; Melnick, A. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood,  2011, 118(13), 3559-3569.
[http://dx.doi.org/10.1182/blood-2011-06-357996] [PMID: 21828137] 
[49] 
Dominguez, P.M.; Teater, M.; Chambwe, N.; Kormaksson, M.; Redmond, D.; Ishii, J.; Vuong, B.; Chaudhuri, J.; Melnick, A.; Vasanthakumar, A.; Godley, L.A.; Papavasiliou, F.N.; Elemento, O.; Shaknovich, R. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Rep.,  2015, 12(12), 2086-2098.
[http://dx.doi.org/10.1016/j.celrep.2015.08.036] [PMID: 26365193] 
[50] 
Teater, M.; Dominguez, P.M.; Redmond, D.; Chen, Z.; Ennishi, D.; Scott, D.W.; Cimmino, L.; Ghione, P.; Chaudhuri, J.; Gascoyne, R.D.; Aifantis, I.; Inghirami, G.; Elemento, O.; Melnick, A.; Shaknovich, R. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat. Commun.,  2018, 9(1), 222.
[http://dx.doi.org/10.1038/s41467-017-02595-w] [PMID: 29335468] 
Rights & Permissions Print Cite
Article Metrics
52
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1568009620666210106122750	Print ISSN 1568-0096
Publisher Name Bentham Science Publisher	Online ISSN 1873-5576
Current Cancer Drug Targets

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract
